Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV—Acute Coronary Syndrome) Trial
J.P. Ottervanger,Paul W. Armstrong,Elliott Barnathan,Eric Boersma,J.S. Cooper,Erik Magnus Ohman,Stefan James,Eric J. Topol,Lars Wallentin,Maarten L. Simoons +9 more
Reads0
Chats0
TLDR
Compared with placebo, abciximab did not provide any survival benefit at 1 year in patients admitted with an acute coronary syndrome with ST depression and/or elevated troponin who were not scheduled to undergo early coronary revascularization.Abstract:
BACKGROUND: This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention. METHODS AND RESULTS: A total of 7800 patients were included with an acute coronary syndrome without ST elevation, documented by either elevated cardiac troponin or transient or persistent ST-segment depression. They were randomized to abciximab bolus and 24-hour infusion, abciximab bolus and 48-hour infusion, or matching placebo. The overall 1-year mortality rate was 8.3% (649 patients). One-year mortality was 7.8% in the placebo group and 8.2% in the 24-hour and 9.0% in the 48-hour abciximab infusion group. Compared with placebo, the hazard ratio for the 24-hour infusion of abciximab was 1.1 (95% CI 0.86 to 1.29), and for the 48-hour infusion, it was 1.2 (95% CI 0.95 to 1.41). The lack of benefit of abciximab was observed in every subgroup studied. Patients with negative troponin or elevated C-reactive protein had a higher mortality rate after treatment with abciximab for 48 hours than with placebo: 8.5% versus 5.8% in those with negative troponin (P=0.02), 16.3% versus 12.1% in those with elevated C-reactive protein (P=0.04). CONCLUSIONS: Compared with placebo, abciximab did not provide any survival benefit at 1 year in patients admitted with an acute coronary syndrome with ST depression and/or elevated troponin who were not scheduled to undergo early coronary revascularization. In subgroups of patients, in particular those with low cardiac troponin or elevated C-reactive protein, abciximab was associated with excess mortality.read more
Citations
More filters
Journal ArticleDOI
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Ezra A. Amsterdam,Nanette K. Wenger,Ralph G. Brindis,Donald E. Casey,Theodore G. Ganiats,David R. Holmes,Allan S. Jaffe,Hani Jneid,Rosemary F. Kelly,Michael C. Kontos,Glenn N. Levine,Philip R. Liebson,Debabrata Mukherjee,Eric D. Peterson,Marc S. Sabatine,Richard W. Smalling,Susan J. Zieman +16 more
TL;DR: In this article, Anderson et al. discuss the FAHA chair election process and discuss the state of the art in the field of cancer research. But they do not discuss the role of women in this process.
Journal ArticleDOI
Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies
Abel Romero-Corral,Victor M. Montori,Virend K. Somers,Josef Korinek,Randal J. Thomas,Thomas G. Allison,Farouk Mookadam,Francisco Lopez-Jimenez +7 more
TL;DR: The better outcomes for cardiovascular and total mortality seen in the overweight and mildly obese groups could not be explaining by adjustment for confounding factors and could be explained by the lack of discriminatory power of BMI to differentiate between body fat and lean mass.
Journal ArticleDOI
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Hani Jneid,Jeffrey L. Anderson,R. Scott Wright,Cynthia D. Adams,Charles R. Bridges,Donald E. Casey,Steven M. Ettinger,Francis M. Fesmire,Theodore G. Ganiats,A. Michael Lincoff,Eric D. Peterson,George J. Philippides,Pierre Theroux,Nanette K. Wenger,James P. Zidar +14 more
TL;DR: In this article, the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons developed a guideline for the management of stroke patients.
Journal ArticleDOI
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Jeffrey L. Anderson,Cynthia D. Adams,Elliott M. Antman,Charles R. Bridges,Robert M. Califf,Donald E. Casey,William E. Chavey,Francis M. Fesmire,Judith S. Hochman,Thomas N. Levin,A. Michael Lincoff,Eric D. Peterson,Pierre Theroux,Nanette K. Wenger,R. Scott Wright,Hani Jneid,Steven M. Ettinger,Theodore G. Ganiats,George J. Philippides,Alice K. Jacobs,Jonathan L. Halperin,Nancy M. Albert,Mark A. Creager,David L. DeMets,Robert A. Guyton,Frederick G. Kushner,E. Magnus Ohman,William G. Stevenson,Clyde W. Yancy +28 more
TL;DR: This poster presents a poster presented at the 2016 American Academy of Thoracic Surgeons conference on “Cardiovascular Angiography and Interventions: Foundations of Cardiovascular and Pulmonary Rehabilitation,” presented in Los Angeles, USA.
Journal ArticleDOI
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Ezra A. Amsterdam,Nanette K. Wenger,Ralph G. Brindis,Donald E. Casey,Theodore G. Ganiats,David R. Holmes,Allan S. Jaffe,Hani Jneid,Rosemary F. Kelly,Michael C. Kontos,Glenn N. Levine,Philip R. Liebson,Debabrata Mukherjee,Eric D. Peterson,Marc S. Sabatine,Richard W. Smalling,Susan J. Zieman +16 more
TL;DR: Early hospital care as discussed by the authors is a special case of early hospital care, which is a type of early medical care that requires early evaluation and management, and early admission evaluation of patients.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Salim Yusuf,Zhao F,Shamir R. Mehta,Susan Chrolavicius,Gianni Tognoni,K K Fox,Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators +6 more
TL;DR: The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
Journal ArticleDOI
ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina)
Eugene Braunwald,Elliott M. Antman,John W. Beasley,Robert M. Califf,Melvin D. Cheitlin,Judith S. Hochman,Robert H. Jones,Dean J. Kereiakes,Joel Kupersmith,Thomas N. Levin,Carl J. Pepine,John W. Schaeffer,Earl E. Smith,David E Steward,Pierre Theroux,Raymond J. Gibbons,Joseph S. Alpert,David P. Faxon,Valentin Fuster,Gabriel Gregoratos,Loren F. Hiratzka,Alice K. Jacobs,Sidney C. Smith +22 more
TL;DR: The present guidelines supersede the 1994 guidelines and summarize both the evidence and expert opinion and provide final recommendations for both patient evaluation and therapy.
Journal ArticleDOI
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
TL;DR: Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.
Journal ArticleDOI
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
TL;DR: Inhibition of the platelet glycoprotein IIb/IIIa receptor with abciximab, together with low-dose, weight-adjusted heparin, markedly reduces the risk of acute ischemic complications in patients undergoing percutaneous coronary revascularization, without increasing the riskof hemorrhage.
Related Papers (5)
ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina)
Eugene Braunwald,Elliott M. Antman,John W. Beasley,Robert M. Califf,Melvin D. Cheitlin,Judith S. Hochman,Robert H. Jones,Dean J. Kereiakes,Joel Kupersmith,Thomas N. Levin,Carl J. Pepine,John W. Schaeffer,Earl E. Smith,David E Steward,Pierre Theroux,Raymond J. Gibbons,Joseph S. Alpert,David P. Faxon,Valentin Fuster,Gabriel Gregoratos,Loren F. Hiratzka,Alice K. Jacobs,Sidney C. Smith +22 more